肠道白色念珠菌通过IL-17A与Trem2+巨噬细胞促进肝细胞癌进展及抗PD-1耐药
研究分析肝细胞癌、肝硬化及健康对照的粪便与肿瘤样本,并结合多种小鼠肝癌模型,发现肠道白色念珠菌丰度在肝癌患者中升高且与不良预后相关。机制上,白色念珠菌经IL-17A-MCP-1/PAI-1轴招募并极化Trem2+巨噬细胞,抑制CD8+ T细胞功能,并损害抗PD-1疗效。
要点
- 肝癌患者粪便白色念珠菌丰度升高,与晚期、总生存缩短及持久临床获益减少相关。
- 白色念珠菌经IL-17A诱导Trem2+巨噬细胞聚集,抑制CD8+ T细胞浸润与功能。
- 抗真菌治疗可部分恢复抗PD-1疗效,提示其作为生物标志物与治疗靶点的潜力。
核心结论
- 肠道白色念珠菌通过IL-17A-Trem2+巨噬细胞环路促进肝细胞癌进展并介导抗PD-1耐药。
研究设计与样本
- 分析肝细胞癌、肝硬化及健康对照的粪便与肿瘤样本,采用ITS2测序与免疫分析。
- 机制研究整合四种同源小鼠肝癌模型及细胞实验,结合单细胞与批量RNA测序、遗传与药物干预、Kaede光转换、真菌抗原 recall 实验、抗真菌治疗与抗PD-1治疗。
主要发现
- 肝癌患者粪便白色念珠菌丰度高于对照,并与晚期疾病、较短总生存及持久临床获益减少相关。
- 白色念珠菌灌胃增加小鼠肿瘤负荷,诱导Th17/IL-17A偏倚微环境,伴Trem2+巨噬细胞聚集及CD8+ T细胞浸润与功能受损。
- 抗真菌治疗减轻肿瘤进展,而IL-17A阻断或缺失 largely 消除白色念珠菌相关的肿瘤促进作用。
- IL-17A经ACT1-TRAF6-TAK1信号诱导肿瘤源性MCP-1招募巨噬细胞,并上调PAI-1激活TGF-β/Smad3促进Trem2+巨噬细胞免疫抑制状态。
- Trem2+巨噬细胞通过抑制CXCL10与诱导GAL-1限制CD8+ T细胞招募与效应功能,并可能经IL-1β和IL-6强化Th17反应。
关键数值与推荐
- Kaede光转换显示肠系膜淋巴结至肝脏的Th17迁移增强,真菌抗原 recall 实验显示Th17对白色念珠菌优先应答。
- 白色念珠菌在体内损害抗PD-1疗效,抗真菌治疗部分恢复治疗反应性。
临床怎么用
- 粪便白色念珠菌丰度及该免疫环路组分或可作为患者分层生物标志物与联合治疗靶点。
- 抗真菌治疗目前仅在小鼠中作为概念验证干预,临床转化需更大前瞻性研究与更选择性治疗策略。
局限性
- 临床关联基于样本量有限的观察性队列。
- 抗真菌治疗仅在小鼠中作为概念验证干预进行测试。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Whether intestinal fungal dysbiosis contributes to hepatocellular carcinoma (HCC) progression and resistance to immune checkpoint inhibitors (ICIs) remains unclear. We investigated how gut Candida albicans influences HCC progression, immune remodeling, and response to ICI therapy. METHODS: Fecal and tumor samples from patients with HCC, liver cirrhosis, and healthy controls were analyzed using ITS2 sequencing, immune profiling, and correlation analyses. Mechanistic studies focused on four complementary autochthonous murine HCC models and cell-based assays, integrating single-cell and bulk RNA sequencing, genetic and pharmacologic perturbations, Kaede photoconversion, fungal antigen recall assays, antifungal treatment, and anti-PD-1 therapy. RESULTS: Fecal C. albicans abundance was higher in HCC patients and was associated with advanced disease, shorter overall survival, and reduced durable clinical benefit. Across HCC models, C. albicans gavage increased tumor burden and induced a Th17/IL-17A-skewed microenvironment characterized by Trem2+ macrophage accumulation and impaired CD8+ T cell infiltration and function. Antifungal treatment attenuated tumor progression, whereas IL-17A blockade or deficiency largely abrogated C. albicans-associated tumor promotion. Mechanistically, IL-17A induced tumor-derived MCP-1 through ACT1-TRAF6-TAK1 signaling to recruit macrophages and upregulated PAI-1, which activated TGF-β/Smad3 signaling to promote an immunosuppressive Trem2+ macrophage state. These macrophages limited CD8+ T cell recruitment and effector function through coordinated CXCL10 repression and GAL-1 induction, while potentially reinforcing Th17 responses through IL-1β and IL-6. Kaede photoconversion demonstrated enhanced mesenteric lymph node-to-liver Th17 trafficking, while fungal antigen recall assays revealed preferential Th17 responsiveness to C. albicans. C. albicans also impaired anti-PD-1 efficacy in vivo, whereas antifungal treatment partially restored therapeutic responsiveness. CONCLUSIONS: Intestinal C. albicans promotes HCC progression and anti-PD-1 resistance through an IL-17A-Trem2+ macrophage circuit, supporting its potential as a biomarker and therapeutic target. IMPACT AND IMPLICATIONS: Intestinal fungal dysbiosis is increasingly recognized as a component of the gut-liver axis, but its functional contribution to HCC has remained poorly defined. Our study identifies intestinal Candida albicans as a promoter of HCC progression in experimental models and delineates an IL-17A-MCP-1/PAI-1-Trem2+ macrophage circuit that links fungal exposure to impaired CD8+ T-cell immunity and reduced response to PD-1 blockade. These findings are relevant to researchers and clinicians seeking microbiome-associated determinants of HCC progression and immunotherapy resistance. Fecal C. albicans abundance and components of this immune circuit may warrant evaluation as biomarkers for patient stratification and as potential targets for combination therapy. However, the clinical associations reported here are based on modest observational cohorts, and antifungal treatment was tested as a proof-of-concept intervention in mice. Larger prospective studies and more selective therapeutic approaches will therefore be required before these findings can inform clinical management.
引用
- Zhang L, Wang K, Chai D, et al. Intestinal Candida albicans promotes HCC progression and anti-PD-1 resistance via IL-17A and Trem2+ macrophages. J Hepatol. 2026. PMID: 42933735. doi:10.1016/j.jhep.2026.10.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。